EVK Evonik Industries AG
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silanes for the automotive, tire, electronics, and cosmetics industries; and D-/L-methionine and lysine for animal nutrition. Its Custom Solutions segment provides additives for coatings, adhesives, sealants, polyurethane foams, and lubricants for the cosmetic, cleaning, and pharmaceutical industries. The Infrastructure segment engages in the infrastructure activities and offers butadiene, MTBE, butene-1, isononanol, and DINP for use in the plastic and packaging industries, production of rubber and fuels, and as plasticizers in the construction and automotive sectors. The company was founded in 1847 and is headquartered in Essen, Germany.…
Industry Peers
Specialty ChemicalsKey Statistics
About Evonik Industries (ETR: EVK)
›
Evonik Industries (ETR: EVK) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 30,319 employees.
The shares were at 18.25 EUR on 19 November 2026, up 25.4% over 52 weeks. Its 52-week range is 12.49 EUR to 22.52 EUR: the price is 19.0% below the high and 46.1% above the low.
At a market capitalisation of 8.50B EUR, it trades at 49.3 times trailing earnings and 11.9 times forward earnings. The median trailing P/E of its 18 largest Specialty Chemicals peers is 34.0, a premium of 45% for EVK. It pays a dividend yielding 4.53% (it pays out 270% of its earnings), against a median of 1.76% among the dividend payers in that peer group.
Evonik Industries reports return on equity of 3.3%, an operating margin of 5.4% and revenue up 12.8% year over year.
Its debt exceeds its cash by 3.42B EUR, a debt-to-equity ratio of 0.48. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 11 analysts cover the stock, with an average rating of Hold; their mean price target of 19.55 EUR is 7.1% above the current price. The next earnings report is expected on 4 March 2027.